Nucleoside-Lipid-Based Nanocarriers for Sorafenib Delivery
Abstract Although the application of sorafenib, a small inhibitor of tyrosine protein kinases, to cancer treatments remains a worldwide option in chemotherapy, novel strategies are needed to address the low water solubility (< 5 μM), toxicity, and side effects issues of this drug. In this context...
Main Authors: | Sebastien Benizri, Ludivine Ferey, Bruno Alies, Naila Mebarek, Gaelle Vacher, Ananda Appavoo, Cathy Staedel, Karen Gaudin, Philippe Barthélémy |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2018-01-01
|
Series: | Nanoscale Research Letters |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s11671-017-2420-2 |
Similar Items
-
Nucleoside-Lipid-Based Nanoparticles for Phenazine Delivery: A New Therapeutic Strategy to Disrupt Hsp27-eIF4E Interaction in Castration Resistant Prostate Cancer
by: Hajer Ziouziou, et al.
Published: (2021-04-01) -
Thioredoxin Downregulation Enhances Sorafenib Effects in Hepatocarcinoma Cells
by: María José López-Grueso, et al.
Published: (2019-10-01) -
Trehalose-Based Nucleolipids as Nanocarriers for Autophagy Modulation: An In Vitro Study
by: Anthony Cunha, et al.
Published: (2022-04-01) -
Autophagy-Related Chemoprotection against Sorafenib in Human Hepatocarcinoma: Role of FOXO3 Upregulation and Modulation by Regorafenib
by: Flavia Fondevila, et al.
Published: (2021-10-01) -
Effect of <i>Allium senescens</i> Extract on Sorafenib Resistance in Hepatocarcinoma Cells
by: Sohyeon Park, et al.
Published: (2021-04-01)